21 USC 379j-12 - Authority to assess and use animal drug fees

U.S Code last checked for updates: Nov 22, 2024

§ 379j–12.

Authority to assess and use animal drug fees

(a)

Types of fees

Beginning in fiscal year 2004, the Secretary shall assess and collect fees in accordance with this section as follows:

(1)

Animal drug application and supplement fee

(A)

In general

Each person that submits, on or after September 1, 2003, an animal drug application or a supplemental animal drug application shall be subject to a fee as follows:

(i)

A fee established in subsection (c) for an animal drug application, except an animal drug application subject to the criteria set forth in section 360b(d)(4) of this title.

(ii)

A fee established in subsection (c), in an amount that is equal to 50 percent of the amount of the fee under clause (i), for—

(I)

a supplemental animal drug application for which safety or effectiveness data are required;

(II)

an animal drug application subject to the criteria set forth in section 360b(d)(4) of this title; and

(III)

an application for conditional approval under section 360ccc of this title of a new animal drug for which an animal drug application submitted under section 360b(b)(1) of this title has been previously approved under section 360b(d)(1) of this title for another intended use.

(B)

Payment

(C)

Exceptions for previously filed application or supplement

(i)

If an animal drug application or a supplemental animal drug application was submitted by a person that paid the fee for such application or supplement, was accepted for filing, and was not approved or was withdrawn (without a waiver or refund), the submission of an animal drug application or a supplemental animal drug application for the same product by the same person (or the person’s licensee, assignee, or successor) shall not be subject to a fee under subparagraph (A).

(ii)

Beginning with fiscal year 2019, in the case of an animal drug application submitted by a person under section 360b(b)(1) of this title, where such person (or their licensor, assignor, or predecessor-in-interest) previously submitted an application for conditional approval under section 360ccc of this title for the same product and paid the applicable fee under subparagraph (A), the application under section 360b(b)(1) of this title shall not be subject to a fee under subparagraph (A) if submitted within the timeframe specified in section 360ccc(h) of this title.

(D)

Refund of fee if application refused for filing

(E)

Refund of fee if application withdrawn

(2)

Animal drug product fee

(A)

In general

Each person—

(i)

who is named as the applicant in an animal drug application or supplemental animal drug application for an animal drug product which has been submitted for listing under section 360 of this title; and

(ii)

who, after September 1, 2003, had pending before the Secretary an animal drug application or supplemental animal drug application,

shall pay for each such animal drug product the annual fee established in subsection (c).

(B)

Payment; fee due date

Such fee shall be payable for the fiscal year in which the animal drug product is first submitted for listing under section 360 of this title, or is submitted for relisting under section 360 of this title if the animal drug product has been withdrawn from listing and relisted. After such fee is paid for that fiscal year, such fee shall be due each subsequent fiscal year that the product remains listed, upon the later of—

(i)

the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees for such fiscal year under this section; or

(ii)

January 31 of each year.

(C)

Limitation

(3)

Animal drug establishment fee

(A)

In general

Each person—

(i)

who owns or operates, directly or through an affiliate, an animal drug establishment;

(ii)

(iii)

who, after September 1, 2003, had pending before the Secretary an animal drug application or supplemental animal drug application,

shall be assessed an annual establishment fee as established in subsection (c) for each animal drug establishment listed in its approved animal drug application as an establishment that manufactures the animal drug product named in the application.

(B)

Payment; fee due date

(i)

the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees for such fiscal year under this section; or

(ii)

January 31 of each year.

(C)

Limitation

(4)

Animal drug sponsor fee

(A)

In general

Each person—

(i)

who meets the definition of an animal drug sponsor within a fiscal year; and

(ii)

who, after September 1, 2003, had pending before the Secretary an animal drug application, a supplemental animal drug application, or an investigational animal drug submission,

shall be assessed an annual sponsor fee as established under subsection (c).

(B)

Payment; fee due date

The fee under this paragraph for a fiscal year shall be due upon the later of—

(i)

the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees for such fiscal year under this section; or

(ii)

January 31 of each year.

(C)

Limitation

(b)

Fee revenue amounts

(1)

In general

(2)

Types of fees

Of the total revenue amount established for a fiscal year under paragraph (1)—

(A)

20 percent shall be derived from fees under subsection (a)(1) (relating to animal drug applications and supplements);

(B)

27 percent shall be derived from fees under subsection (a)(2) (relating to animal drug products);

(C)

26 percent shall be derived from fees under subsection (a)(3) (relating to animal drug establishments); and

(D)

27 percent shall be derived from fees under subsection (a)(4) (relating to animal drug sponsors).

(c)

Annual fee setting; adjustments

(1)

Annual fee setting

Not later than 60 days before the start of each fiscal year beginning after September 30, 2023, the Secretary shall—

(A)

establish for that fiscal year animal drug application fees, supplemental animal drug application fees, animal drug sponsor fees, animal drug establishment fees, and animal drug product fees based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and

(B)

publish such fee revenue amounts and fees in the Federal Register.

(2)

Inflation adjustment

(A)

For fiscal year 2025 and subsequent fiscal years, the revenue amounts established in subsection (b) shall be adjusted by the Secretary by notice, published in the Federal Register, for a fiscal year, by multiplying such revenue amounts by an amount equal to the sum of—

(i)

one;

(ii)

the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 of the preceding 4 fiscal years for which data are available, multiplied by the average proportion of personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 years of the preceding 4 fiscal years for which data are available; and

(iii)

the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Arlington-Alexandria, DC–MD–VA–WV; not seasonally adjusted; all items less food and energy; annual index) for the first 3 years of the preceding 4 years for which data are available multiplied by the average proportion of all costs other than personnel compensation and benefits costs to total Food and Drug Administration costs for the first 3 years of the preceding 4 fiscal years for which data are available.

(B)

Compounded basis.—

The adjustment made each fiscal year after fiscal year 2025 under this paragraph shall be applied on a compounded basis to the revenue amount calculated under this paragraph for the most recent previous fiscal year.

(3)

Workload adjustments

(A)

In general

For fiscal year 2025 and subsequent fiscal years, after the fee revenue amounts established under subsection (b) are adjusted for inflation in accordance with paragraph (2), the fee revenue amounts shall be further adjusted for such fiscal year to reflect changes in the workload of the Secretary for the process for the review of animal drug applications, subject to subparagraph (B). With respect to such adjustment—

(i)

such adjustment shall be determined by the Secretary based on a weighted average of the change in the total number of animal drug applications, supplemental animal drug applications for which data with respect to safety or effectiveness are required, manufacturing supplemental animal drug applications, investigational animal drug study submissions, and investigational animal drug protocol submissions submitted to the Secretary;

(ii)

such adjustment shall be made for each fiscal year that the adjustment determined by the Secretary is greater than 3 percent, except for the first fiscal year that the adjustment is greater than 3 percent; and

(iii)

the Secretary shall publish in the Federal Register notice under paragraph (1) the amount of such adjustment and the supporting methodologies.

(B)

Rule of application

(4)

Operating reserve adjustment

(A)

In general

For fiscal year 2025 and each subsequent fiscal year, after the fee revenue amount established under subsection (b) is adjusted in accordance with paragraphs (2) and (3), the Secretary shall—

(i)

increase the fee revenue amount for such fiscal year, if necessary to provide an operating reserve of not less than 12 weeks; or

(ii)

if the Secretary has an operating reserve in excess of the number of weeks specified in subparagraph (C) for that fiscal year, the Secretary shall 1

 So in original. The words “the Secretary shall” also appear at end of introductory provisions.

decrease the fee revenue amount to provide not more than the number of weeks specified in subparagraph (C) for that fiscal year.

(B)

Carryover user fees

(C)

Number of weeks of operating reserves

The number of weeks of operating reserves specified in this subparagraph is—

(i)

22 weeks for fiscal year 2025;

(ii)

20 weeks for fiscal year 2026;

(iii)

18 weeks for fiscal year 2027; and

(iv)

16 weeks for fiscal year 2028.

(D)

Publication

(5)

Limit

(d)

Fee waiver or reduction; exemptions from fees

(1)

Waiver or reduction

The Secretary shall grant a waiver from or a reduction of one or more fees assessed under subsection (a) where the Secretary finds that—

(A)

the assessment of the fee would present a significant barrier to innovation because of limited resources available to such person or other circumstances;

(B)

the fees to be paid by such person will exceed the anticipated present and future costs incurred by the Secretary in conducting the process for the review of animal drug applications for such person;

(C)

the animal drug application or supplemental animal drug application is intended solely to provide for use of the animal drug in—

(i)

a Type B medicated feed (as defined in section 558.3(b)(3) of title 21, Code of Federal Regulations (or any successor regulation)) intended for use in the manufacture of Type C free-choice medicated feeds; or

(ii)

a Type C free-choice medicated feed (as defined in section 558.3(b)(4) of title 21, Code of Federal Regulations (or any successor regulation));

(D)

the animal drug application or supplemental animal drug application is intended solely to provide for a minor use or minor species indication; or

(E)

the sponsor involved is a small business submitting its first animal drug application to the Secretary for review.

(2)

Use of standard costs

(3)

Rules for small businesses

(A)

Definition

(B)

Waiver of application fee

(C)

Certification

(4)

Exemption from fees

(e)

Effect of failure to pay fees

(f)

Assessment of fees

(1)

Limitation

(2)

Authority

(g)

Crediting and availability of fees

(1)

In general

(2)

Collections and appropriation Acts

(A)

In general

The fees authorized by this section—

(i)

subject to subparagraph (C), shall be collected and available in each fiscal year in an amount not to exceed the amount specified in appropriation Acts, or otherwise made available for obligation for such fiscal year, and

(ii)

shall be available to defray increases in the costs of the resources allocated for the process for the review of animal drug applications (including increases in such costs for an additional number of full-time equivalent positions in the Department of Health and Human Services to be engaged in such process) over such costs, excluding costs paid from fees collected under this section, for fiscal year 2003 multiplied by the adjustment factor.

(B)

Compliance

The Secretary shall be considered to have met the requirements of subparagraph (A)(ii) in any fiscal year if the costs funded by appropriations and allocated for the process for the review of animal drug applications—

(i)

are not more than 3 percent below the level specified in subparagraph (A)(ii); or

(ii)

(I)

are more than 3 percent below the level specified in subparagraph (A)(ii), and fees assessed for the fiscal year following the subsequent fiscal year are decreased by the amount in excess of 3 percent by which such costs fell below the level specified in subparagraph (A)(ii); and

(II)

such costs are not more than 5 percent below the level specified in subparagraph (A)(ii).

(C)

Provision for early payments

(3)

Authorization of appropriations

(4)

Excess collections

(h)

Collection of unpaid fees

(i)

Written requests for waivers, reductions, and refunds

(j)

Construction

(k)

Abbreviated new animal drug applications

The Secretary shall—

(1)

to the extent practicable, segregate the review of abbreviated new animal drug applications from the process for the review of animal drug applications; and

(2)

adopt other administrative procedures to ensure that review times of abbreviated new animal drug applications do not increase from their current level due to activities under the user fee program.

(June 25, 1938, ch. 675, § 740, as added Pub. L. 108–130, § 3, Nov. 18, 2003, 117 Stat. 1363; amended Pub. L. 110–316, title I, § 103, Aug. 14, 2008, 122 Stat. 3510; Pub. L. 113–14, title I, § 103, June 13, 2013, 127 Stat. 454; Pub. L. 115–52, title I, § 102(a)(2), Aug. 18, 2017, 131 Stat. 1008; Pub. L. 115–234, title I, § 103, title III, § 304(b), Aug. 14, 2018, 132 Stat. 2428, 2438; Pub. L. 118–15, div. B, title III, § 2303, Sept. 30, 2023, 137 Stat. 87.)

cite as: 21 USC 379j-12